87 results about "Cell necrosis" patented technology

A cell necrosis apparatus is described. The cell necrosis apparatus includes an identification and usage device capable of performing an encrypted handshake protocol with an energy source. The identification and usage device is capable of identifying the cell necrosis apparatus, to prevent the use of unauthorized devices with the energy source, as well as controlling and causing a record to be made of a usage of the cell necrosis apparatus.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

An enhanced method and device are provided to inhibit or reduce restenosis following angioplasty or stent placement. A porous balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the porous balloon such that an exterior surface of the balloon, as well as a portion of the cold working fluid, from the microporosity contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium.

Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.

The present invention provides an enhanced method and device to inhibit or reduce the rate of restenosis following angioplasty or stent placement. The invention involves placing a balloon tipped catheter in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place from a balloon angioplasty. A fluid such as a perfluorocarbon may be flowed into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. The catheter may also be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon is in contact with at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium.

The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.

The invention relates to application of colchicin in preparing drugs, in particular to application of colchicin in pharmacotherapy of cholestatic liver disease, the application of colchicin in preparing a cholestatic liver disease drug, and the application of colchicin in preparing the drug for treating gestation intrahepatic cholestasis syndrome, inner primary cirrhose biliaire, primary sclerosing cholangitis severe jaundice or immunity jaundice cholestatic liver disease. The colchicin can effectively lower liver injury and cholestasis caused by cholestatic liver disease, i.e. the colchicin can effectively treat cholestatic liver disease. The colchicin can effectively lighten hepatic cell necrosis, inflammatory cell infiltration and bile capillary hyperplasia caused by cholestasis. The colchicin can effectively increase bile acid, bilirubin and expression of phospholipid transporters BSEP, MRP2 and MDR3 in a bile duct, accelerates excretion of bile acid, bilirubin and phospholipid deposited in the body and reduces liver damage.

The invention provides a cell necrosis inhibitor, and a preparation method and application thereof. Particularly, the invention provides an inhibitor for inhibiting cell necrosis and/or human receptorinteracting protein 1 kinase (RIP1). The inhibitor has a structure shown as in a following formula I. The compound and a composition comprising the compound are useful in the prevention and/or treatment of diseases involving cell death and/or inflammation.

The invention discloses MLKL protein and an application of the MLKL protein as a target point of a cell necrosis inhibitor. The invention provides the protein represented by the following: (a) the protein comprises the amino acid sequence represented by the sequence 1; (b) the protein comprises the amino acid sequence represented by the sequence 13; (c) the protein is obtained through mutation of threonine on site 357 of the N terminal of the sequence 13 into alanine; (D) the protein is obtained through mutation of serine on the site 358 of the N terminal of the sequence 13 into alanine; (E) the protein comprises the amino acid sequence from the site 179 of the N terminal of the sequence 1 to the site 471 of the N terminal of the sequence 1. The protein is combined with RIP3 protein to provide an apoptosis effect, such that the protein can be used as the target point of anti-apoptosis drugs, and used for screening and developing the anti-apoptosis drugs. The invention further provides compounds for inhibitions of the nucleic acid expressed by the gene and the protein, wherein the compounds can be used as products for inhibitions of the apoptosis. The MLKL protein of the present invention provides important values for medical research and drug development.

Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

Methods and compositions for modulating necrosis and for treating neurological and cardiovascular diseases are described. The inventors have shown that BNIP3 is involved in cell necrosis and cell death involved in cardiovascular and neurological diseases.

The invention which belongs to the technical field of gene engineering relates to a male-sterile gene TCL, a coded protein thereof, a promoter thereof, a plasmid thereof and a host cell thereof. The male-sterile gene TCL of the invention is a gene which codes the following protein of (a) or (b): (a) a protein which is composed of an amino acid sequence represented by SEQ ID NO:2; and (b): a protein which has the activity of influencing tapetal programmed cell death, is derived from (a), and is obtained through substituting, deleting or adding one or some amino acids. The invention also relates to the promoter with a base sequence represented by SEQ ID NO:3, the protein with the amino acid sequence represented by the SEQ ID NO:2, and the plasmid and the host cell of the gene with a base sequence represented by SEQ ID NO:1. The TCL gene of the present invention has the function of maintaining tapetal programmed cell death of the paddy rice anther,and the deletion of the gene function can cause tapetal cell necrosis and male sterility of the paddy rice.

The invention discloses application of adenosine and derivatives thereof in prevention and treatment of medicament-induced liver injury, relating to application of adenosine and derivatives thereof such as adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in protection of acetaminophen-induced liver injury. A mouse model adopted in the application is an acetaminophen-induced mouse acute hepatic failure model, the dosage of the adenosine or derivatives thereof is 0.1 to 5mmol/kg, and the adenosine and derivatives thereof can reduce the activities of aspartate aminotransferase (AST) and alanine transaminase (ALT) in the medicament-induced liver injury, reduce the substantial cell necrosis area and improve the glutathione level so as to prevent and treat the acetaminophen-induced liver injury caused by liver toxic medicaments. Animal experiments prove that the adenosine and derivatives thereof have a significant effect on preventing and treating the medicament-induced liver injury, so the adenosine and derivatives thereof can be used for the preventing and treating processes of the medicament-induced liver injury, and a new method and means are provided for clinically treating the medicament-induced liver injury.

The invention discloses protein BxCDP1 of bursaphelenchus-xylophilus pathogen-associated molecular patterns and application thereof. The amino acid sequence of the protein BxCDP1 of the pathogen-associated molecular patterns (PAMPS) is shown in SEQID NO.2. From effectors secreted by bursaphelenchus xylophilus and the PAMP, the defensive responses of a host plant, namely, a pine tree, to bursaphelenchus xylophilus invasion are studied, the protein BxCDP1 of the pathogen-associated molecular patterns is obtained from the bursaphelenchus xylophilus, it is proven through experiments that the protein BxCDP1 can trigger cell necrosis of various plants including the host plant, has a certain broad spectrum in cell necrosis triggering, and stimulates the defensive response of the host plant. The BxCDP1 triggered cell necrosis depends on a co-receptor BAK1 of pattern recognition receptors, the BxCDP1 can stimulate the accumulation of nicotiana benthamiana ROS and up regulation of PTI Marker genes, and the immunoreaction of the nicotiana benthamiana is stimulated. It can be seen that the BxCDP1 is a PAMP secreted by the bursaphelenchus xylophilus, and has important theoretical and practicalsignificance for revealing the pathogenic mechanism of the bursaphelenchus xylophilus and improving the resistance of the pine tree to the bursaphelenchus xylophilus in a targeted mode.

The invention provides a multiplex PCR primer set, a kit and a method for simultaneous detection of EHV (Eel herpes virus), JEECV (Japanese eel endothelial cells-infecting virus) and AmPV (Anguilla marmorata polyoma-like virus). According to obtained nucleic acid sequences, specific primers for amplification of EHV, JEECV and AmPV are designed to avoid formation of stable primer dimmers between primers, specificity of primer amplified sequences is analyzed to obtain the primer set that is composed of 6 nucleic acid sequences including SEQ ID NO:1-6 and has high amplification sensitivity and specificity on EHV, JEECV and AmPV simultaneously. The multiplex PCR primer set, kit and method provided by the invention can simultaneously detect and identify EHV, JEECV and AmPV in one PCR reaction system, have the advantages of simple operation and strong specificity, etc., and can directly determine the result according to different amplification lengths, thus being more efficient and practical.

A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells.

The invention relates to use of JMJD3 inhibitor in preparing medicine for preventing and treating pancreatitis, which belongs to the field of a medicine. The present invention provides the use of a JMJD3 inhibitor for preparing a medicine for preventing and treating pancreatitis. The animal experiments show that JMJD3 specific inhibitor GSK-J4 can significantly improve pathological lesions such asacinar cell necrosis, edema and inflammatory cell infiltration in pancreatitis model mice, the ratio of infiltrating monocytes and neutrophils in pancreas and lung tissue is reduced, the percentage of TNF-alpha positive monocytes in pancreas, lung and peripheral blood is reduced, and a significant therapeutic effect on pancreatitis is exerted. The use provides a new biological therapeutic targetfor the treatment of pancreatitis, and by detecting the relevant indicators of human clinical pancreatic tissue and blood samples, the use of JMJD3 specific inhibitor GSK-J4 for the treatment of patients with pancreatitis is feasible.